重组人血小板生成素对肺癌化疗患者血小板输注效果的影响  

Impact analysis of rh TPO apheresis platelet transfusion on lung cancer patients with chemotherapy

作　　者：关晓珍[1] 孙晓琳[1] 杨璐[1] 潘雪[1] 刘丽[1] 于洋[1] 汪德清[1] GUAN Xiaozhen;SUN Xiaolin;YANG Lu;PAN Xue;LIU Li;YU Yang;WANG Deqing(Dpt of transfusion of PLA Genaral Hospital Beijing 100853)

机构地区：[1]解放军总医院输血科,北京100853

出　　处：《中国输血杂志》2018年第11期1253-1255,共3页Chinese Journal of Blood Transfusion

摘　　要：目的评估肺癌化疗患者预防性使用重组人血小板生成素(rhTPO)对化疗后输注血小板效果的影响。方法应用临床输血智能管理与评估系统(v1. 0),选取本院2015年1月1日—12月31日输注血小板的276名肺癌化疗患者的病历资料,按照是否曾使用rhTPO将患者分为rhTPO组(n=146)和对照组(n=130),比较2组患者年龄、性别、体表面积、体重指数(BMI)、输前血小板计数(Plt)等基线资料,以及血小板输注效果(以血小板校正增高指数判断输注疗效)、输注量。结果 2组患者基线资料数据相近(P>0. 05); rhTPO组146例共输注血小板407 U、对照组130例共输注血小板379 U,2组患者平均血小板输注量(U)分别为2. 97±0. 34 vs 3. 81±0. 14(P<0. 05); 2组患者输注总体为有效(P<0. 05); 2组输注血小板前后均检测血常规的患者比例分别为73. 97%(108/146) vs 76. 15%(99/130),输注有效率分别为86. 9%(279/321) vs 76. 5%(235/307)(P<0. 05)。结论肺癌化疗患者预防性使用rhTPO可减少化疗后异体血小板输注量,且血小板输注效果较未使用rhTPO者高。Objective To evaluate the effect of recombinant human platelet product(rhTPO) on lung cancer patients with chemotherapy. Methods With application of the intelligent management and evaluation system for clinical blood transfusion(v1.0),we selectd the patients with lung cancer recorded during January 1,2015 to December 31,2015. The patients were divided into the rhTPO group(n = 146) and the control group(n = 130),comparing the baseline indexes( age,sex,body mass index,body surface area,platelet count pretransfusion),the effects of platelet transfusion,and Infusion quantity.Results The baseline indexes of the two groups showed no statistically significant differences(P<0. 05);Transfusion volume: 146 cases of rhTPO group(407U),130 cases of control group( 379 U). The mean platelet infusion volume( U) of the two groups was 2. 97±0. 34,3. 81±0. 14( P<0. 05);The infusion was effective in both groups(P<0. 05);The proportion of patients in the group with blood routine examination pre and post platelet transfusion was 73. 97%(108/146) and76. 15%( 99/130),The effective rates of infusion were 86. 9%( 279/321) and 76. 5%(235/307),respectively(P <0. 05).Conclusion The application of rhTPO can significantly reduce the amount of platelets transfusion,and improve the effect in lung cancer patients with chemothery.

关 键 词：重组人血小板生成素(rhTPO) 肺癌 化疗 血小板输注 输血疗效 

分 类 号：R457.1[医药卫生—治疗学] R734.2[医药卫生—临床医学]